How to improve patient education on deep brain stimulation in Parkinson’s disease: the CARE Monitor study
- Lars Dinkelbach†1,
- Bettina Möller†2,
- Karsten Witt2,
- Alfons Schnitzler1 and
- Martin Südmeyer1, 3Email author
© The Author(s). 2017
Received: 19 October 2016
Accepted: 10 February 2017
Published: 21 February 2017
The introduction of deep brain stimulation (DBS) about 25 years ago provided one of the major breakthroughs in the treatment of Parkinson’s disease (PD). However, a high percentage of patients are reluctant to undergo DBS. Previous research revealed that the critical step on the patient’s path to DBS is the decision whether to undergo further diagnostic assessment for surgery at a specialized DBS-center. The aims of the current study were to evaluate how effective the combination of an outpatient DBS screening tool, STIMULUS, with specially developed educational material was to enhance patient education on DBS and to identify motivational aspects which influenced the patients’ willingness to undergo further assessment.
In total, 264 patients were identified as appropriate candidates for DBS by general neurologists using the electronic preselection tool STIMULUS. Patient-centered information material was designed and handed out to support education on DBS. Further, several clinical characteristics and details of the patient counseling were documented. Refusal or consent to show up at a DBS center was registered over the following 16 months.
114 (43.2%) patients preselected as eligible for DBS (STIMULUS Score ≥ 6) agreed to show up at a specialized DBS center to undergo further diagnostic assessment. The patients’ ages, PD classification as an akinetic-rigid type and the talks’ topics side-effects of dopaminergic medication and the optimal time frame had a significant influence on the patients’ decisions.
The combination of preselection tools as STIMULUS with comprehensive information material is effective to increase DBS-acceptance rate in PD patients. Important topics of the information about DBS cover the optimal time frame for DBS surgery, the side-effects of dopaminergic medication as well as side-effects and complications of DBS surgery.
KeywordsDeep brain stimulation Parkinson’s disease Treatment acceptance Patient education Referral
Chronic DBS is a well-tolerated, beneficial and widely established treatment for Parkinson’s disease [1, 2]. The selection process usually consists of two steps: A general neurologist preselects the patients and refers them to a specialized DBS center which takes the final decision for or against surgery based on comprehensive diagnostic assessment.
Bearing in mind that the risk of surgery rises with age while the benefit tends to decrease [3, 4], the right timing for a recommendation to undergo DBS treatment is crucial and merely depends on the evaluation by the general neurologist. Nevertheless, the decision seems to be a struggle for general neurologists as only 48 to 55% of the patients initially referred to DBS centers were later assessed as appropriate candidates for surgery [5, 6]. In order to support the preselection, Moro and colleagues developed an online screening tool called STIMULUS . This tool aids the general neurologists in the referral of patients with a range of registered demographic and clinical parameters. The application of STIMULUS could decisively improve the preselection process as 77% of referred patients were later assessed as appropriate candidates by the DBS center .
Despite the high accuracy for preselection, this study raises another issue: After 6 months, only 28% of patients with referral as recommended by STIMULUS actually showed up at the DBS center, mainly due to patients’ reluctance to undergo surgery . During further assessment in the DBS center, only 6% of patients were excluded for reasons such as poor motivation .
The need for patient information provided by professionals is highlighted by a questionnaire study, addressing the attitude of Parkinson patients and their relatives towards DBS . The study suggests that the main factors leading to refusal were unrealistic doubts and mixed expectations of this treatment , as a result of insufficient information provided predominantly by the media or other patients [8, 9].
The aim of the CARE Monitor study was to improve patient education for DBS and to identify key factors that influence the patients’ decision to undergo further diagnostic assessment at a specialized DBS-center. For this purpose, 51 general neurologists located all over Germany were trained on how to operate the STIMULUS screening tool and to use a newly developed information material. Approval from the ethics committee of the Heinrich Heine University, Düsseldorf was obtained (N: 4641). All data were collected anonymously.
Construction of the information material
Based upon patients’ doubts and expectations as revealed by a questionnaire study , a comprehensive information booklet was developed to support physicians in educating the patients about DBS. In 26 pages, the benefits, risks and right timing of DBS as well as its procedure for Parkinson’s disease are described. A DVD was attached to the booklet, including a 4-minute film illustrating the DBS procedure for treating Parkinson’s disease. The German version of the booklet as well as the film are available at http://www.medtronic-caremonitor.de.
In view of the exploratory nature of our study, we decided to perform a stepwise approach to identify the predictive factors leading to patients’ consent. First, Mann-Whitney U tests (for ordinal and scaled data), Chi-Square tests (for nominal data with more than two categories) and Fisher’s exact tests (for nominal data with two categories) were applied to identify candidate variables with a potential influence on patients’ decisions. Subsequently, variables with a significant relationship to patients’ decisions (p < 0.05) were stated as candidate variables and thus included in a stepwise binary logistic regression. For categorical data, dummy variables were created. Due to this stepwise approach, we could ensure that at least ten outcome cases were provided for each predictor variable . All analyses were conducted using IBM SPSS Statistics 22 (International Business Machines Corporation, Armonk, USA).
Within 16 months of the initial consultation visit, 114 (43.2%) out of 264 preselected patients (STIMULUS Score ≥ 6) consented to show up at a specialized DBS center. The newly designed information material was well accepted and stated to be “helpful” by 156 (78.4%) patients (“uncertain” n = 28, 14.1% “not helpful” n = 15, 7.5%, n = 65 missing values). Accordingly, the patients’ evaluation of the information material had a highly significant correlation with patients’ decisions (p < 0.001).
Correlation between patients’ consent to be referred to a DBS center, clinical characteristics and the contents of clarification sessions
N = 114 (43.2%)
N = 150 (56.8%)
Hoehn & Yahr Stage
Eligibility for DBS (STIMULUS Score)
Number of topics addressed in the clarification talk
Evaluation of the information material
Patient with DBS
Contents of clarification talk‡
quality of life
side effects of medication
optimal time frame
change of role model in partnership
evidence of DBS
experience with DBS
complications of DBS surgery
side effects of DBS
effects of medication withdrawal
progression of PD
Coefficients of the predictive regression model
95% Confidence Interval
Clarification talk contents
optimal time frame
side effects of medication
Poor consent to undergo DBS surgery is one of the major problems of this treatment, as only 28%  of Parkinson patients consented in the referral to a specialized DBS-center, even after being preselected as promising candidates for this treatment. Thus, a large majority of patients were not reached to undergo a potentially beneficial treatment.
The resulting regression model of our study suggests that the consultation visit to provide information on DBS plays a key role in patients’ decisions, whereas the disease severity as evaluated by the Hoehn & Yahr Stages or subjective impairment as well as the clinical eligibility for DBS measured by the STIMULUS score do not. Of the various topics that could be addressed, the fact that, whether or not the side-effects of dopaminergic medication and the optimal time frame for DBS (meaning rising risks in surgery with age while benefits decrease [3, 4]) were mentioned in the patients’ education had the greatest predictive value for patients’ consent. The relevance of right timing is supported by the significant predictive value of the patient’s age as the rate of consent decreased with age. Interestingly, mentioning negative aspects of DBS during the consultation visit, such as the risks and complications of the surgery or side-effects of the stimulation, had no negative effect on patients’ approval, even in our exploratory initial analysis without a correction for multiple comparisons (see Table 1). Descriptively, a slight trend towards higher approval after mentioning these factors could be noted-a hint, that overdrawn fears of patients are a greater problem than unrealistic expectations, as described in a previous survey . Therefore, we highly recommend that negative aspects of DBS should not be avoided with the intent to not frighten patients. This should rather be an obligatory topic to be addressed during the education for DBS, not least for ethical reasons.
In our study, patients with an akinetic-rigid subtype of Parkinson’s disease had a significantly higher likelihood to consent to the referral to a DBS-center, despite recently published evidence indicating higher benefit of DBS for other subtypes, such as the tremor dominant . Possibly, akinetic-rigid patients are in greater need for alternative treatments as the prevalence of this subtype contributes to a poorer quality of life . On the other hand, we were not able to find a relationship between the patients’ subjective impairment and their decisions. However, we cannot completely rule out a mediating effect of the patients’ quality of life as we did not apply a conventional measurement of quality of life such as the PDQ-39 assessment.
An ongoing discussion addresses the common finding that approximately twice as many men are recipients of DBS than women [14, 15] even though epidemiology studies suggest an equal distribution of Parkinson’s disease [16, 17]. With regard to clinical eligibility for DBS, no gender differences were found, suggesting that non-biological factors may be accountable for this prominent gender discrepancy in DBS recipients . Setiawan and coworkers proposed that women may have more doubts or fears regarding DBS . In line with previous results, the current study could reproduce the typical gender distribution as only 92 (34.8%) women were preselected as eligible candidates for DBS. In contrast to Setiawan and colleagues’ assumption, the patients’ genders were not related to their decision to undergo DBS. Hence, the reasons for the gender distribution of parkinsonian patients undergoing DBS remain unclear.
In our study, 31.8% of the patients consented to the referral within the first 6 months after the initial screening, the same time interval as in Wächter and colleagues’ trial  (see Additional file 2:Figure S1). Although this ratio indicates only a slight increase of approval with the usage of information material, it probably underestimates its effect. The current study was designed to follow the patients’ decision for 16 months and the participating neurologists were therefore not obliged to report consent within the first 6 months. In the total 16-month period of the study, 114 (43.2%) of the 264 patients who were preselected as eligible for DBS consented to show up at a specialized DBS-center. Therefore, our data indicates that adequate training of general neurologists and support with information materials for patients and their relatives can increase the rate of approval for DBS treatment. This assumption is supported by the high correlation of patients’ evaluation of the information material to their decisions (see Table 1). Accordingly, our data emphasize the usefulness of information materials such as booklets or DVDs as an effective and low-cost method to support the patient counseling for DBS.
Even though our data clearly indicate a strong relevance of the patient information, no causal connections can be deduced because our study is lacking a control group receiving no or reduced information about DBS. Further, our data only cover a German cohort and thus should be interpreted with caution regarding other health-care systems.
Adequate patient education by general neurologists is fundamental to allay patients’ aversion to DBS and should cover the optimal time frame to undergo surgery as well as dopaminergic side-effects which could be avoided by DBS treatment. Negative aspects of this therapy should not be evaded and are an obligatory topic in any ethical clarification session. Specialized, patient-centered information material provides a low-cost and effective way to additionally support education about DBS.
Deep brain stimulation
Parkinson`s Disease Questionnaire
Structuring of the information material, training of the participating neurologists and subsequent data collection were funded by Medtronic International. We would like to thank all participating neurologists and DBS-centers.
This study was funded by Medtronic International.
Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.
LD and MS drafted the manuscript. LD, BM and MS designed and executed the statistical analysis. LD, BM, KW, AS and MS interpreted the data and critically revised the manuscript. LD conducted this work in partial fulfillment of the requirements for an MD thesis. All authors read and approved the final manuscript.
KW receives grants from the German Research Council and the German Ministry of Education and Health and receives fees and honoraria from TEVA, GlaxoSmithKline, Medtronic and Desitin. AS has received speaker’s fees and payment for the development of educational presentations, consultancy fees, and travel expenses from Medtronic. MS has received speaker’s fees and/or honoraria for consultancy by Teva, Medtronic, St. Jude Medical, Novartis, Meda, and AbbVie. LD and BM have nothing to disclose.
Consent for publication
Ethics approval and consent to participate
All data were collected anonymously. No biometric or retraceable information was obtained. Patients were verbally informed regarding the anonymous data collection and asked for their consent. The anonymous data collection and its analyzation was reviewed and approved by the ethics committee of the Heinrich Heine University, Düsseldorf (N: 4641).
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Bronstein JM, Tagliati M, Alterman RL, Lozano AM, Volkmann J, Stefani A, Horak FB, Okun MS, Foote KD, Krack P, et al. Deep brain stimulation for Parkinson disease: an expert consensus and review of key issues. Arch Neurol. 2011;68(2):165.View ArticlePubMedGoogle Scholar
- Deuschl G, Schade-Brittinger C, Krack P, Volkmann J, Schäfer H, Bötzel K, Daniels C, Deutschländer A, Dillmann U, Eisner W, et al. A randomized trial of deep-brain stimulation for Parkinson’s disease. N Engl J Med. 2006;355(9):896–908.View ArticlePubMedGoogle Scholar
- Pahwa R, Factor S, Lyons K, Ondo W, Gronseth G, Bronte-Stewart H, Hallett M, Miyasaki J, Stevens J, Weiner W. Practice Parameter: Treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review) Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2006;66(7):983–95.View ArticlePubMedGoogle Scholar
- de Souza RM, Moro E, Lang AE, Schapira AH. Timing of deep brain stimulation in Parkinson disease: a need for reappraisal? Ann Neurol. 2013;73(5):565–75.View ArticleGoogle Scholar
- Katz M, Kilbane C, Rosengard J, Alterman RL, Tagliati M. Referring patients for deep brain stimulation: an improving practice. Arch Neurol. 2011;68(8):1027–32.View ArticlePubMedGoogle Scholar
- Wächter T, Mínguez-Castellanos A, Valldeoriola F, Herzog J, Stoevelaar H. A tool to improve pre-selection for deep brain stimulation in patients with Parkinson’s disease. J Neurol. 2011;258(4):641–6.View ArticlePubMedGoogle Scholar
- Moro E, Allert N, Eleopra R, Houeto J-L, Phan T-M, Stoevelaar H. A decision tool to support appropriate referral for deep brain stimulation in Parkinson’s disease. J Neurol. 2009;256(1):83–8.View ArticlePubMedGoogle Scholar
- Südmeyer M, Volkmann J, Wojtecki L, Deuschl G, Schnitzler A, Möller B. Tiefe Hirnstimulation-Erwartungen und Bedenken. Nervenarzt. 2012;83(4):481–6.View ArticlePubMedGoogle Scholar
- Hamberg K, Hariz G-M. The decision-making process leading to deep brain stimulation in men and women with parkinson’s disease-an interview study. BMC Neurol. 2014;14(1):89.View ArticlePubMedPubMed CentralGoogle Scholar
- Peduzzi P, Concato J, Kemper E, Holford TR, Feinstein AR. A simulation study of the number of events per variable in logistic regression analysis. J Clin Epidemiol. 1996;49(12):1373–9.View ArticlePubMedGoogle Scholar
- Cohen J. A power primer. Psychol Bull. 1992;112(1):155–9.View ArticlePubMedGoogle Scholar
- Katz M, Luciano MS, Carlson K, Luo P, Marks WJ, Larson PS, Starr PA, Follett KA, Weaver FM, Stern MB, et al. Differential effects of deep brain stimulation target on motor subtypes in Parkinson’s disease. Ann Neurol. 2015;77(4):710–9.View ArticlePubMedGoogle Scholar
- Schrag A, Jahanshahi M, Quinn N. What contributes to quality of life in patients with Parkinson’s disease? J Neurol Neurosurg Psychiatry. 2000;69(3):308–12.View ArticlePubMedPubMed CentralGoogle Scholar
- Hariz G-M, Nakajima T, Limousin P, Foltynie T, Zrinzo L, Jahanshahi M, Hamberg K. Gender distribution of patients with Parkinson’s disease treated with subthalamic deep brain stimulation; a review of the 2000–2009 literature. Parkinsonism Relat Disord. 2011;17(3):146–9.View ArticlePubMedGoogle Scholar
- Setiawan M, Kraft S, Doig K, Hunka K, Haffenden A, Trew M, Longman S, Ranawaya R, Furtado S, Lee R. Referrals for movement disorder surgery: under-representation of females and reasons for refusal. Can J Neurol Sci. 2006;33(01):53–7.View ArticlePubMedGoogle Scholar
- de Rijk M, Tzourio C, Breteler M, Dartigues J, Amaducci L, Lopez-Pousa S, Manubens-Bertran J, Alperovitch A, Rocca W. Prevalence of parkinsonism and Parkinson’s disease in Europe: the EUROPARKINSON Collaborative Study. European Community Concerted Action on the Epidemiology of Parkinson’s disease. J Neurol Neurosurg Psychiatry. 1997;62(1):10–5.View ArticlePubMedPubMed CentralGoogle Scholar
- Linder J, Stenlund H, Forsgren L. Incidence of Parkinson’s disease and parkinsonism in northern Sweden: A population‐based study. Mov Disord. 2010;25(3):341–8.View ArticlePubMedGoogle Scholar
- Morgante L, Morgante F, Moro E, Epifanio A, Girlanda P, Ragonese P, Antonini A, Barone P, Bonuccelli U, Contarino MF. How many parkinsonian patients are suitable candidates for deep brain stimulation of subthalamic nucleus? Results of a questionnaire. Parkinsonism Relat Disord. 2007;13(8):528–31.View ArticlePubMedGoogle Scholar